BACKGROUND/OBJECTIVES: Randomised controlled trials (RCTs) evaluating the effect of fish oil supplementation on postoperative atrial fibrillation (POAF) following cardiac surgery have produced mixed results. In this study, we examined relationships between levels of red blood cell (RBC) n-3 long-chain polyunsaturated fatty acids (LC-PUFAs) and the incidence of POAF. SUBJECTS/METHODS: We used combined data (n ¼ 355) from RCTs conducted in Australia and Iceland. The primary end point was defined as POAF lasting 410 min in the first 6 days following surgery. The odds ratios (ORs) for POAF were compared between quintiles of preoperative RBC n-3 LC-PUFA levels by multivariable logistic regression. RESULTS: Subjects with RBC docosahexaenoic acid (DHA) in the fourth quintile, comprising a RBC DHA range of 7.0-7.9%, had the lowest incidence of POAF. Subjects in the lowest and highest quintiles had significantly higher risk of developing POAF compared with those in the fourth quintile (OR ¼ 2.36: 95% CI; 1.07-5.24 and OR ¼ 2.45: 95% CI; 1.16-5.17, respectively). There was no association between RBC eicosapentaenoic acid levels and POAF incidence.
INTRODUCTION
Atrial fibrillation (AF) is a common postoperative complication of cardiac surgery, which is associated with increased length of hospital or intensive care unit (ICU) stay and increased morbidity and mortality. [1] [2] [3] Preoperative dietary fish oil was initially reported to reduce the incidence of postoperative AF (POAF) in patients undergoing coronary artery bypass graft (CABG) surgery, 4 but subsequent studies have reported disparate results. [5] [6] [7] [8] [9] [10] Although consistent evidence from randomised controlled trials (RCTs) is required to establish efficacy of an intervention, analysis of RCTs of n-3 long-chain polyunsaturated fatty acids (LC-PUFAs) or fish oil interventions by group can be problematic. A cardiac benefit from n-3 LC-PUFAs is assumed to be derived from incorporation into tissue phospholipids, and unlike a drug or device trial, where the active intervention is either present or absent, n-3 LC-PUFAs are ubiquitous in cellular membranes. A recent multivariate analysis from the Framingham Heart Study found that dietary intake of eicosapentaenoic acid (EPA) þ docosahexaenoic acid (DHA) and fish oil supplementation accounted for only 25% and 15%, respectively, of the variability of RBC EPA þ DHA. 11 In addition, incorporation of n-3 LC-PUFAs into tissue phospholipids may take up to 4-6 weeks to approach maximal levels. 12 Thus, in a controlled clinical trial with fish oil, individual n-3 LC-PUFA levels will depend not only on the group allocation which includes dose and length of supplementation, but also on baseline n-3 LC-PUFA levels, background dietary intake and a range of genetic, anthropometric and lifestyle variables, which in a short-term supplementation trial will result in a large degree of overlap in tissue n-3 LC-PUFA levels between the treatment and control groups. In addition to the factors above, there is a potential nonlinearity in the association between n-3 LC-PUFA levels and POAF, 13 which could further weaken the by-group analysis of RCTs.
In order to seek reasons for the disparate results of the RCTs of fish oil supplementation and incidence of POAF, we have examined the association between levels of the n-3 LC-PUFA EPA and DHA and the n-6 LC-PUFA arachidonic acid (AA) in RBC membrane lipids and the incidence of POAF in a large cohort of patients undergoing open heart surgery.
METHODS
This analysis included subjects from RCTs conducted in Reykjavík, Iceland 5 and Adelaide, Australia. 7 The studies had similar inclusion/exclusion criteria; both studies excluded patients with a previous diagnosis of AF, or current use of class I or class III anti-arrhythmic drugs, and both included patients undergoing CABG and valve surgery. The Icelandic study excluded patients o40 years, whereas the minimum age in the Australian study was 18 years. The Australian study excluded from the RCT patients consuming fish oil supplements or habitually consuming 41 fish meal per week. However, a number of those excluded patients with higher background n-3 LC-PUFA intakes were consented to obtain a blood sample and clinical data, and they are included in this analysis. All subjects underwent surgical intervention as clinically indicated, and none underwent concurrent atrial ablation. The experimental interventions in the RCTs were supplementation with 1.24 g/d EPA þ 1.00 g/d DHA (Reykjavik) and 2.7 g/d EPA þ 1.8 g/d DHA (Adelaide) prior to surgery.
The studies were approved by the Human Research Ethics Committee of the Royal Adelaide Hospital, and the Bioethics Committee of LandspitaliThe National University Hospital of Iceland (62-2004 ) and the Icelandic Data Protection Authority.
Peripheral venous blood was collected either on the day prior to or on the day of surgery. RBC lipids were extracted with isopropanol/chloroform (1:2 in Adelaide and 2:1 in Reykjavik). In Adelaide, lipids were extracted from RBC, phospholipids were separated by thin layer chromatography and after methanolysis of the phospholipid fractions, fatty acid methyl esters were analysed by gas liquid chromatography as previously described.
14 In Reykjavik, fatty acid methyl esters of RBC total lipids were analysed by gas chromatography (Agilent 6890 N, Agilent, Palo Alto, CA, USA) using a Chrompack CP-SIL 8CB column (25 m Â 250 mm i.d. Â 0.12 mm film thickness) and hydrogen as the carrier gas. Oven temperature commenced at 150 1C for 4 min, increased at 4 1C per min to 230 1C and then at 20 1C per min to 280 1C, which was maintained for 4 min. The injector and detector temperatures were 280 and 300 1C, respectively. Using measurements against commercial standards (Nu-Chek-Prep, Elysian, MN, USA), RBC fatty acid values are presented as % weight of total fatty acids with chain length from C 14 to C 24 .
We compared the difference between RBC total and RBC phospholipid EPA þ DHA in six samples with a range of EPA þ DHA values of 2.6-10.6% of total fatty acids. The mean ( ± S.D.) difference between total and phospholipid EPA þ DHA values was 0.22% (±0.17) of total fatty acids. Thus, the methodological differences between Adelaide and Reykjavik are minor and allow the pooling of fatty acid data from the two sites.
All subjects were managed in a dedicated cardiac intensive care unit following surgery. Postoperative management was in accordance with the routine care within each institution. A minimum of 72 h of continuous electrocardiographic monitoring was performed. Following this, subjects underwent daily 12-lead electrocardiogram until discharge from hospital with further continuous monitoring if there were any symptoms or signs to suggest POAF.
The primary outcome measure was the occurrence of sustained POAF or atrial flutter of duration X10 min or requiring intervention. In the Australian study, the primary end point was the occurrence of POAF in the first 6 days post surgery or until discharge if earlier, whereas in the Icelandic study, it was the occurrence of POAF until discharge from the hospital or maximum of 2 weeks post surgery. To standardise the end point to 6 days, subjects in the Icelandic study who had their first occurrence of POAF after day 6 (n ¼ 3) were deemed not to have had an episode of POAF.
Data analysis and statistics
Patient characteristics, surgical type and study site were examined individually as predictors of POAF, using Fisher's exact test for categorical variables and logistic regression for continuous variables. Variables with Pp0.1 were included as potential confounders in the multivariate model as described below.
The risk of the primary end point according to the levels of RBC LC-PUFAs (EPA, DHA, EPA þ DHA and AA) was assessed by multivariate logistic regression, initially using the fatty acid levels as a continuous variable and subsequently as categories based on quintiles of the relevant fatty acid. Analyses were undertaken in the standard manner with quintile 1 being the reference and also with the quintile with the lowest odds ratio (OR) being the reference. Multivariate adjustment was undertaken using potential confounders that had univariate P-values of p0.10 between those with and without POAF (that is, study site, age, surgical procedure (valve±CABG vs CABG only), diabetes, body mass index (BMI) and statin use.
Missing data were excluded casewise. Analyses were performed using Statistica Version 9.1 (StatSoft Inc., Tulsa, OK, USA) and SAS Version 9.2 (SAS Institute Inc., Cary, NC, USA).
RESULTS
This analysis included 355 patients; 160 from the Icelandic study and 195 from the Australian study that had full data on fatty acid levels. AF occurred in 160 (45%) patients, and baseline demographic and clinical details of the patients are provided in Table 1 . Those with POAF were older (Po0.0001), were more likely to have had valve surgery (P ¼ 0.01) and had a lower BMI (P ¼ 0.008) than those without POAF. Further, the patients with POAF had higher RBC DHA level (P ¼ 0.02) and lower RBC AA level (P ¼ 0.003) than those without POAF. There was also a difference in POAF incidence between the Adelaide and Reykjavik study sites, where the POAF incidence was higher (P ¼ 0.007) in the Reykjavik study (Table 1) .
When RBC EPA levels were analysed as a continuous variable, there was no relationship with POAF incidence on univariate or multivariate analyses. When analysed by quintiles, there were no clear relationships between quintiles of RBC EPA and the risk of POAF on multivariate analysis using either the first quintile (that is, with the lowest EPA levels) or the quintile with the lowest OR (that is, with the lowest POAF risk) as the reference (Table 2) .
When RBC DHA levels were analysed as a continuous variable, there was a significant relationship between RBC DHA and POAF incidence on univariate analysis (OR ¼ 1.19: 95% CI; 1.03-1.38) but this disappeared on correction for age, site, surgery type, diabetes, statin use and BMI in multivariate analysis (OR ¼ 0.99: 95% CI; 0.82-1.21). However, the relationship between quintiles of RBC DHA levels and POAF incidence was clearly nonlinear (Table 3) . When using the first quintile as reference, only the fourth quintile was associated with significantly lower risk of POAF incidence (OR ¼ 0.42: 95% CI; 0.19-0.94), and when using the fourth quintile as the reference, there was a significantly increased risk of POAF in the lowest and highest quintiles of RBC (OR ¼ 2.36: 95% CI; 1.07-5.24 and OR ¼ 2.45: 95% CI; 1.16-5.17, respectively).
There was no relationship between RBC EPA þ DHA levels as a continuous variable and POAF incidence on univariate analysis or multivariate analysis. However, the relationship between quintiles of RBC EPA þ DHA and POAF incidence was similar to that of RBC DHA in being nonlinear (Table 4) . Using the first quintile as the reference, the OR of POAF incidence was lowest in the fourth When RBC AA was analysed as a continuous variable, there was a significant relationship between RBC AA and POAF incidence on univariate analysis (OR ¼ 0.83: 95% CI; 0.73-0.94). This relationship was in the opposite direction to that with DHA. However, the relationship disappeared on correction for age, site, surgery type, diabetes, statin use and BMI. There was no clear relationship between quintiles of RBC AA and the risk of POAF incidence on multivariate analysis using either the first quintile or the quintile with the lowest OR as the reference (Table 5) .
DISCUSSION
In this study, we have combined data from two separate studies, one conducted in Iceland and the other in Australia, to examine relationships between the preoperative levels of RBC n-3 LCPUFAs and the risk of developing POAF in patients undergoing cardiac surgery. The main finding was the possibility of U-shaped relationship between RBC DHA or EPA þ DHA levels and risk of POAF. The risk was consistently lowest when the RBC EPA þ DHA was in the range of about 9.2% to about 10.4% of total fatty acids. However, above this level the risk of POAF increased significantly.
The multivariate analysis in this study was corrected for the potential confounders that were identified in univariate analysis by having Pp0.1 (Table 1) . This included the type of surgery, CABG or valve, which had a significant interaction with the relationship between fish oil and POAF in one meta-analysis 15 but not in another. 16 Extended aortic cross-clamp time is a risk factor for POAF. 1 The data in this manuscript are not corrected for cross-clamp time because 21 patients had off-pump surgery. However, analysis only of the by-pass surgery data showed little or no difference after correction for cross-clamp time (see Supplementary Information) . Also, the largest of the RCTs that examined the effects of fish oil on POAF reported no interaction with the cross-clamp time. 10 Observational studies have reported reduced risk of incident AF with increased fish intake or with serum n-3 PUFAs. [17] [18] [19] Persistent AF after cardioversion was decreased by a fish oil intervention in one study, but others have not shown benefits and meta-analysis shows no benefits of fish oil after cardioversion. 20 The triggers for incident AF are likely to be different from those for POAF. However, there are findings with incident AF similar to those in our study where some studies have reported increased risk of AF with increased fish of fish oil intake or blood levels of n-3 PUFAs. A case-control study reported higher serum EPA levels in patients with AF compared with control. 21 A sub-group analysis of the Framingham Heart Study found a sixfold increased risk of incident AF (HR ¼ 6.53: 95% CI; 2.65-16.06) in subjects who habitually consumed more than four meals/week of dark fish, which generally has the highest content of n-3 LC-PUFAs, compared with those who consumed less than one meal/week. 22 In one study recurrence of AF after cardioversion showed a trend towards an increased risk in subjects supplemented with fish oil (HR ¼ 1.22: 95% CI; 0.98-1.52, P ¼ 0.08). 23 It was noted that this has led to a warning about the potential for increased risk of AF in the product information labelling for the omega-3 ethyl ester preparation, Lovaza. 24 The latest report in Abstract only is that of a U-shaped relationship between marine n-3 PUFAs and AF in a Danish cohort. 25 Perhaps the clearest demonstration that n-3 PUFAs can affect atrial physiology was the demonstration that IV n-3 PUFAs administered immediately before cardiac electrophysiology slowed atrial conduction and decreased inducible AF but did have a pro-arrhythmic effect in increasing atrial flutter. 26 Therefore, it is not surprising that it is difficult to discern a pattern of effect of n-3 PUFAs on incident AF or postoperative AF across studies that vary in methodology and dose and end points.
It has been proposed that RBC EPA þ DHA as a percentage of total fatty acids (that is, the Omega-3 Index ) is an independent risk factor for coronary heart disease mortality. 27 With the current state of knowledge, the Omega-3 Index could not be used to make predictions about the risk of AF or POAF, but this may not always be the case.
As most or all drugs have a therapeutic index, it might not be unexpected that the risk of POAF was suppressed at moderate levels of n-3 LC-PUFAs but increased at higher n-3 LC-PUFA levels. It is clear that the physical state of membranes can be altered by DHA with its propensity for rapid conformational change. 28 Therefore, it is possible that the membrane effects at high DHA levels could exceed the physiological norm for correct functioning of some integral membrane proteins. For instance, the molecular activity of the Na þ K þ -ATPase has been shown to be related to the DHA content of the surrounding membrane over a range of tissue types and species, 29 and free or non-esterified n-3 LC-PUFAs have been shown to increase the refractory period for Na þ channel activation. 30 Another possibility for the effects of n-3 LC-PUFAs on cardiac function could involve eicosanoids. Supplementation with fish oil resulted in a 1 for 1 exchange between EPA þ DHA and AA. 12 The decreased atrial AA after increased consumption of n-3 LC-PUFAs, either through dietary intake or supplementation, could alter eicosanoid production as both AA and EPA are substrates for cyclooxygenase and lipoxygenase enzymes that produce a diverse array of bioactive eicosanoids that often have antagonistic actions. 31 The range of EPA þ DHA where the risk of AF is minimised in this study may represent the optimal balance in these eicosanoids for POAF. Low levels of n-3 LC-PUFAs are associated with overproduction of AA-derived eicosanoids, and has long been associated with inflammatory disease. 32 However, it is possible that excessive displacement of AA by very high n-3 LC-PUFAs could lead to an imbalance between n-3-and n-6 LC-PUFAs-derived eicosanoids that is unfavourable for POAF.
Although our study is the largest analysis of tissue LC-PUFA levels in association with POAF, it does have limitations. First, it is a post-hoc analysis of data derived from two separate single centre studies and the associations observed can only be regarded as hypothesis generating.
There were also minor differences in the protocol of the two studies, including the difference in the duration of PUFA supplementation. However, as it is the biomarker RBC EPA þ DHA that is being examined, the various factors responsible for its value, only some of which will be dose and time, are not important. Although this secondary use of data from two RCTs is ideal for generating a wide range of RBC EPA þ DHA values, the range is probably larger than that in a community cohort study. Finally, although we have corrected for several confounders, there may be unmeasured confounders.
Nevertheless, a U-shaped relationship could explain the inconsistent results obtained in RCTs of fish oil supplementation and POAF incidence if the RBC EPA þ DHA range associated with protection was exceeded in the negative studies 5-7,9,10 but not in the positive studies. 4, 8 It has not been possible to examine this because only one study reported RBC fatty acids. 7 Although RCTs are analysed by group allocation, it is the tissue n-3 LC-PUFA levels that are the ultimate effectors and these will depend on baseline levels, dose and time of intervention and may depend even more on non-dietary factors. 11 The suggestion of conducting fish oil RCTs by using a treat-totarget Omega-3 Index approach would address these issues. The adoption of this methodology in clinical trials of fish oil with cardiac end points would test treatment efficacy more efficiently than the current methods. 
